26159-34-2 Usage
Non-steroidal anti-inflammatory analgesic
Naproxen sodium is a non-steroidal anti-inflammatory analgesic drug which is more tolerable to human, belonging to the phenylpropionic acid compounds. It plays anti-inflammatory effect by inhibiting prostaglandin synthesis.It is absorbed rapidly after oral administration and the plasma reached the peak concentration within 2 to 4 hours. Food has little effect on the rate of absorption. Naproxen and plasma protein are highly binded(99%); the plasma concentration is between 23~40mcg/ml. The metabolic process is demethylation and then combining with glucuronide; the elimination half-life is 12 to 15 hours, mainly excreted by the urine. Clinical application is to relieve a variety of mild to moderate degree of pain, such as tooth extraction and other postoperative pain, primary dysmenorrhea and headache. It is also used for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, juvenile arthritis, tendinitis, bursitis and acute gouty arthritis; it also plays a role in arthritis pain, swelling and activity restricted symptom. Psoriatic arthritis and Reiter's syndrome can also be treated with this product. Compared with ibuprofen, fenoprofen, aspirin, sulindac and indomethacin, the symptom relief effect was similar, but the incidence and severity of adverse reactions in the gastrointestinal and neurological systems were low. In addition, this product is also the same as aspirin which can inhibit platelet aggregation and prolong bleeding time; but the effect is reversible, and can be restored after stopping.
Naproxen sodium and plasma protein binding rate is high (99%), and other protein-binding drugs can be replaced by its joint out. Therefore, the acceptance of these drugs (such as oral anticoagulants, sulfonylurea, hydantoins) people should observe the interaction effects. At the same time the application of probenecid, naproxen can increase the plasma concentration, half-life period. Magnesium hydroxide, aluminum can make this product absorption rate slightly lower; sodium bicarbonate can make it higher.
Uses
Different sources of media describe the Uses of 26159-34-2 differently. You can refer to the following data:
1. Used as anti-inflammatory analgesic
2. Naproxen (Aleve, Anaprox) is a COX inhibitor for COX-1 and COX-2 with IC50 of 8.7 μM and 5.2 μM, respectively
3. A cyclooxygenase inhibitorNaproxen sodium acts as a nonselective inhibitor of Cox-1 and Cox-2. It serves as an anti-inflammatory agent with analgesic and antipyretic properties. Further, it is used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea and acute gout.
Chemical Properties
White Powder
Definition
ChEBI: The sodium salt of naproxen.
Brand name
Aleve (Bayer); Anaprox (Roche);Naprelan (Stat Trade).
General Description
Naproxen sodium (NS) is a sodium salt of propionic acid derivative and demonstrates analgesic, anti-pyretic, and anti-inflammatory properties. It exhibits efficiency in being used as an indomethacin in the treatment of acute musculoskeletal disorders. It belongs to the group of nonsteroidal anti-inflammatory drugs (NSAIDS) and acts by inhibiting the activity of both the cyclooxygenase enzymes, COX-1 & COX-2 and further blocking the synthesis of certain prostaglandins. It is administered in the treatment of ankylosing spondylitis, osteoarthritis, rheumatoid disorders, acute gout, mild to moderate pain, tendonitis, bursitis, dysmenorrhea, fever, and migraine headache. Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Biological Activity
Non-selective cyclooxygenase (COX) inhibitor that displays anti-inflammatory, antipyretic and analgesic effects. Has a neuroprotective role against colchicine-induced cognitive impairment and oxidative stress.
Biochem/physiol Actions
Cyclooxygenase (Prostaglandin H synthase 1 and 2) inhibitor.
references
[1]. mendias cl, tatsumi r and allen re. role of cyclooxygenase-1 and -2 in satellite cell proliferation, differentiation, and fusion. muscle nerve, 2004, 30(4):497-500.[2]. hinz b, cheremina o, besz d, et al. impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. int j clin pharmacol ther, 2008, 46(4):180-6.[3]. sances g, martignoni e, fioroni l, et al. naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. headache, 1990, 30(11):705-9.[4]. tavolari s, bonafè m, marini m, et al. licofelone, a dual cox/5-lox inhibitor, induces apoptosis in hca-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. carcinogenesis, 2008, 29(2):371-80.
Check Digit Verification of cas no
The CAS Registry Mumber 26159-34-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,1,5 and 9 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 26159-34:
(7*2)+(6*6)+(5*1)+(4*5)+(3*9)+(2*3)+(1*4)=112
112 % 10 = 2
So 26159-34-2 is a valid CAS Registry Number.
InChI:InChI=1/C14H14O3.Na/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10;/h3-9H,1-2H3,(H,15,16);/q;+1/p-1/t9-;/m0./s1
26159-34-2Relevant articles and documents
A Ru(II)-p-cymene compound bearing naproxen-pyridineamide. Synthesis, spectroscopic studies, computational analysis and in vitro anticancer activity against lung cells compared to Ru(II)-p-cymene-naproxen and the corresponding drug ligands
Tabares, Julie Pauline Gaitan,Santos, Rodrigo Luis S.R.,Cassiano, Jefferson Luiz,Zaim, Marcio H.,Honorato, Jo?o,Batista, Alzir A.,Teixeira, Sarah F.,Ferreira, Adilson Kleber,Viana, Rommel B.,Martínez, Sandra Quispe,Stábile, Antonio Carlos,de Oliveira Silva, Denise
, p. 27 - 38 (2019)
The design of new Ru(II) organometallics is a subject of interest to the field of anticancer metallodrugs. This work reports the interaction of the Ru(II)-η6-p-cymene framework with naproxen-pyridineamide (Npxpya, L1), a structurally modified form of the naproxen (HNpx, HL2) drug, to give the new organometallic [Ru(η6-p-cymene)(L1)Cl2] (1) bearing the Npxpya ligand. The reported naproxenate-derived, [Ru(η6-p-cymene)(L2)Cl] (2), is re-prepared, also from the precursor [Ru(η6-p-cymene)Cl2]2 (3), and additional investigation is performed. The two Ru(II)-arenes and the L1 ligand are fully characterized by ESI-MS, NMR, ATR/FT-IR and UV/VIS, and their structures corroborated by DFT computational calculations. Time-dependent 1H MNR studies show that both Ru(II)-arenes, despite being stable in non-coordinating solvents, undergo distinct step dissociation in dimethylsulfoxide solvent to give the corresponding drug ligands and [Ru(η6-p-cymene)(dmso)Cl2] (4) species. Electronic absorption spectroscopy experimental data show good correlation with DFT calculations. Organometallics 1 and 2, as well as their corresponding parent drug ligands, exhibit luminescence properties mainly associated to the naproxen moiety. Screening in NCI-H460 and A549 lung cancer cells reveals lack of activity for 2 and L2, while the new organometallic 1 is found to inhibit cell proliferation of both types of cell lines in similar way to the L1 drug. The structural modification, by inserting the pyridineamide moiety into the original structure of naproxen to form the Npxpya conjugated drug, is shown to be crucial for the anticancer activity. Compound 1, despite having IC50 close to the IC50 of L1, does not show significant effect on the mitochondrial membrane potential (MMP), in contrast to the behavior of the free L1 parent drug which significantly decreases the MMP in NCI-H460 cells. Interestingly, since 1H MNR studies indicate that organometallic 1 is completely dissociated in dmso (the solvent used to prepare the drug solutions for cell treatment in the biological assays) to give the L1 free drug and species 4, it is plausible to infer that the presence of Npxpya-free Ru species, probably in the form of species 4, might play a role in inhibiting the mechanism related to the mitochondrial function when the cells are treated with 1, in comparison with the cell treatment with the L1 free drug.
NAPROXCINOD PROCESS AND SOLID DISPERSION
-
Page/Page column 28, (2009/12/28)
Processes for the preparation of naproxcinod and its purification, solid dispersions of naproxcinod with a pharmaceutically acceptable carrier, and processes for making dispersions. Also provided is crystalline 2-(S)-(4-chlorobutyl)-2-(6-methoxy-2-naphthyl)-propanoate and methods for its preparation.
Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate
-
, (2008/06/13)
Novel and very useful forms of sodium (S)-2-(6-methoxy-2-naphthyl)propionate are provided. These forms are sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate having an average particle size significantly larger than about 70 microns--the size of conventional sodium (S)-2-(6-methoxy-2-naphthyl)propionate--and a chiral purity of at least 98% (S)-enantiomer. Process technology enabling the production of such novel products is also described. The provision of such novel products makes possible significant improvements in processing time, plant capacity and product handling operations.
